Tolcapone
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tolcapone: From Parkinson's Disease (COMT Inhibition) to Rasmussen Subacute Encephalitis
One-Sentence Summary
Tolcapone is a COMT (catechol-O-methyltransferase) inhibitor; per the evidence pack's own rationale notes, its established pharmacology relates to catecholamine metabolism in Parkinson's disease as an adjunct to levodopa (no formal Taiwan/Germany regulatory record is available in this dataset). The TxGNN model's top prediction is Rasmussen Subacute Encephalitis, but this is a pure model-driven association with 0 clinical trials and 0 publications, and the evidence pack explicitly states no known mechanistic overlap between COMT inhibition and this disease's T-cell–mediated neuronal injury. Evidence strength for this specific prediction is minimal (L5) and does not currently support further development.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in Taiwan/Germany regulatory data (per evidence pack rationale, tolcapone is a COMT inhibitor classically used as adjunct therapy in Parkinson's disease) |
| Predicted New Indication | Rasmussen Subacute Encephalitis |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Germany Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is marked as a data gap (DG002) in this evidence pack. Based on the mechanistic notes accompanying the predictions, tolcapone acts as a COMT inhibitor, altering catecholamine (dopamine) metabolism — a mechanism whose established clinical relevance is in dopaminergic disorders such as Parkinson's disease.
Rasmussen subacute encephalitis, in contrast, is an autoimmune epilepsy syndrome whose core pathology is T-cell–mediated neuronal destruction. The evidence pack's own repurposing rationale states there is no known intersection between the dopamine/catecholamine metabolic pathway and this disease's immunological mechanism, and characterizes this top-ranked prediction as a "data-driven association rather than a biological hypothesis."
It is worth noting that lower-ranked predictions in this same evidence pack show comparatively stronger (though still limited) mechanistic plausibility — for example, Lewy body dementia (rank 6, L4) is linked via DOPAL/α-synuclein biochemistry, and juvenile parkinsonism (rank 10, L4) is linked via tolcapone's established dopaminergic pharmacology. These may warrant separate evaluation, but per the reporting scope the top-ranked candidate (Rasmussen subacute encephalitis) does not currently have a defensible mechanistic rationale.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Germany Market Information
No German market authorizations found in this evidence pack (total_licenses = 0; market_status = Not marketed).
Safety Considerations
Please refer to the package insert for safety information.
(Note: TFDA/BfArM label warnings and contraindications are flagged in this evidence pack as a Blocking data gap (DG001) — safety data could not be verified for this candidate.)
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction (Rasmussen subacute encephalitis) has no supporting clinical trials, no literature, and an explicitly stated absence of mechanistic plausibility in the evidence pack itself — this is a model-score-only association (L5) and does not meet the bar for further evaluation.
To proceed, the following is needed:
- Resolve DG001 (Blocking): obtain TFDA/BfArM label warnings and contraindications before any safety-stage evaluation can begin
- Resolve DG002 (High): obtain confirmed drug MOA data from DrugBank to properly assess mechanistic linkage
- Confirmed original indication and regulatory history for tolcapone (currently absent from this evidence pack)
- If pursuing repurposing signals from this dataset, consider re-scoping evaluation toward the higher-plausibility candidates identified within the same pack (Lewy body dementia, juvenile parkinsonism) rather than the top TxGNN-ranked but mechanistically unsupported candidate
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.